论文部分内容阅读
目的分析乳腺肿瘤患者血清PF4、VEGF浓度及组织中MVD-CD31的表达及其临床意义。方法选取乳腺浸润性导管癌患者60例,乳腺良性肿瘤患者30例(对照组),用酶联免疫吸附试验(ELISA)检测患者血清中PF4、VEGF蛋白表达,用免疫组化法检测MVD-CD31的表达,了解PF4、VEGF及MVD-CD31的变化规律,分析三者与乳腺肿瘤的关系。结果乳腺浸润性导管癌患者和对照组血清PF4浓度分别为(0.354±0.198)ng/ml和(0.225±0.436)ng/ml,二者差异有统计学意义(P=0.006),血清VEGF浓度分别为(15.458±15.819)pg/ml和(7.727±8.307)pg/ml,二者差异有统计学意义(P=0.046),MVD-CD31分别为16.58±9.528和10.40±3.050,二者差异有统计学意义(P=0.005)。乳腺浸润性导管癌患者血清PF4与VEGF呈正相关(r=0.693,P=0.001),血清PF4与MVDCD31表达无相关性(r=0.01,P=0.947),血清VEGF与MVD-CD31表达无相关性(r=-0.075,P=0.605)。结论PF4可以作为乳腺浸润性导管癌早期诊断的血清学标志物应用于临床。VEGF是鉴别乳腺良、恶性疾病的一个重要指标。乳腺浸润性导管癌患者血清PF4、VEGF表达之间呈正相关。
Objective To analyze the serum levels of PF4 and VEGF and the expression of MVD-CD31 in breast cancer patients and their clinical significance. Methods Sixty patients with invasive ductal carcinoma of the breast and 30 patients with benign breast tumors were enrolled in this study. The expression of PF4 and VEGF in serum was detected by enzyme linked immunosorbent assay (ELISA). The expression of MVD-CD31 To understand the changes of PF4, VEGF and MVD-CD31, and to analyze the relationship between them and breast tumors. Results The serum levels of PF4 in patients with invasive ductal carcinoma of breast and controls were (0.354 ± 0.198) ng / ml and (0.225 ± 0.436) ng / ml, respectively, with statistical significance (P = 0.006) (15.458 ± 15.819) pg / ml and (7.727 ± 8.307) pg / ml respectively, the difference was statistically significant (P = 0.046) and MVD-CD31 were 16.58 ± 9.528 and 10.40 ± 3.050 Significance (P = 0.005). There was no correlation between serum PF4 and MVDCD31 expression (r = 0.01, P = 0.947), serum VEGF and MVD-CD31 expression in patients with breast invasive ductal carcinoma (r = -0.075, P = 0.605). Conclusion PF4 can be used as a serological marker for early diagnosis of invasive ductal breast cancer. VEGF is an important indicator of benign and malignant breast diseases. There was a positive correlation between the expression of PF4 and VEGF in breast invasive ductal carcinoma.